Bristol-Myers Squibb's financial position improved, it raised both its EPS guidance and revenue expectations, and Opdivo's ...

In fact, Camzyos’ FDA review in 2021 was extended by three ... profile of aficamten and continue to expect a differentiated label and risk mitigation profile upon its potential approval by ...

Shares of Bristol Myers BMY have lost 20.7% in the past three months compared with the industry ’s decline of 9.6%. The stock ...

Boxed safety warning The label for Camzyos does however include a boxed warning for worsening heart failure, which is tied to the mechanism of the drug in reducing LVEF and the workload on the ...

Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The FDA's request for a REMS and the subsequent ... Analysts raised concerns about differentiation in light of recent updates to Camzyos' REMS and label. Management emphasized their preparedness ...

The FDA is delaying implementation of a rule that would require food companies to print nutritional information on the front labels of their products. The proposed rule was developed by President ...

Camzyos (mavacamten) is a prescription drug that’s used in certain adults with obstructive hypertrophic cardiomyopathy (HCM). Camzyos comes as an oral capsule. Specifically, Camzyos is used in ...

"Higher doses can produce euphoria, and some countries have restricted how tianeptine is prescribed and dispensed or revised the drug label to warn of possible addiction," Makary said. "FDA ...

The US Food and Drug Administration (FDA) and OpenAI have reportedly been discussing a potential partnership that seeks to use artificial intelligence in drug evaluations of the agency.